It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective n ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study published today in Science Translational Medicine.

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Nara Smith shared pictures of her recent eczema flare-ups on Instagram, where the model got candid about her journey with the ...

Being a social media star may seem like the high life but Nara Smith, fashion model-turned-TikTok creator just pulled back the curtain on all that appears glitz and glam by getting candid about her ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

The American Academy of Dermatology says dry, cold air can cause psoriasis and eczema flare-ups. A San Antonio-based ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...